AU2017292918B2 - Methods for treatment of heart failure - Google Patents

Methods for treatment of heart failure Download PDF

Info

Publication number
AU2017292918B2
AU2017292918B2 AU2017292918A AU2017292918A AU2017292918B2 AU 2017292918 B2 AU2017292918 B2 AU 2017292918B2 AU 2017292918 A AU2017292918 A AU 2017292918A AU 2017292918 A AU2017292918 A AU 2017292918A AU 2017292918 B2 AU2017292918 B2 AU 2017292918B2
Authority
AU
Australia
Prior art keywords
mammal
heart failure
oxo
compound
dihydrothieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017292918A
Other languages
English (en)
Other versions
AU2017292918A1 (en
Inventor
Michael E. Mendelsohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardurion Pharmaceuticals Inc
Original Assignee
Cardurion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals Inc filed Critical Cardurion Pharmaceuticals Inc
Publication of AU2017292918A1 publication Critical patent/AU2017292918A1/en
Application granted granted Critical
Publication of AU2017292918B2 publication Critical patent/AU2017292918B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017292918A 2016-07-07 2017-07-07 Methods for treatment of heart failure Active AU2017292918B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359695P 2016-07-07 2016-07-07
US62/359,695 2016-07-07
PCT/US2017/041249 WO2018009899A1 (en) 2016-07-07 2017-07-07 Methods for treatment of heart failure

Publications (2)

Publication Number Publication Date
AU2017292918A1 AU2017292918A1 (en) 2019-02-07
AU2017292918B2 true AU2017292918B2 (en) 2021-11-11

Family

ID=60912319

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017292918A Active AU2017292918B2 (en) 2016-07-07 2017-07-07 Methods for treatment of heart failure

Country Status (7)

Country Link
US (2) US10870656B2 (enExample)
EP (1) EP3481399A4 (enExample)
JP (1) JP2019521192A (enExample)
KR (1) KR20190049691A (enExample)
AU (1) AU2017292918B2 (enExample)
CA (1) CA3030021A1 (enExample)
WO (1) WO2018009899A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781155A4 (en) * 2018-04-17 2021-10-06 Cardurion Pharmaceuticals, LLC THIENOPYRIMIDINE MEGLUMINE SALTS
CA3132895C (en) 2019-03-08 2024-05-14 Transthera Sciences (Nanjing), Inc. Uses of phosphodiesterase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203703A1 (en) * 2005-06-14 2009-08-13 Kotaro Gotanda Thienopyrimidine Derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
AU2005277384B2 (en) * 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
PT2041139E (pt) * 2006-04-26 2012-01-13 Hoffmann La Roche Compostos farmacêuticos
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
KR101721288B1 (ko) * 2010-05-31 2017-03-29 아스카 세이야쿠 가부시키가이샤 티에노피리미딘 유도체의 결정
ES2659043T3 (es) * 2013-10-07 2018-03-13 Bayer Pharma Aktiengesellschaft Tienouracil-carboxamidas cíclicas y su uso

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203703A1 (en) * 2005-06-14 2009-08-13 Kotaro Gotanda Thienopyrimidine Derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONG I. LEE ET AL, "Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease", NATURE, London, (2015-03-01), vol. 519, no. 7544, doi:10.1038/nature14332, ISSN 0028-0836, pages 472 - 476 *

Also Published As

Publication number Publication date
US10870656B2 (en) 2020-12-22
JP2019521192A (ja) 2019-07-25
US20210261567A1 (en) 2021-08-26
KR20190049691A (ko) 2019-05-09
CA3030021A1 (en) 2018-01-11
EP3481399A4 (en) 2020-04-01
EP3481399A1 (en) 2019-05-15
AU2017292918A1 (en) 2019-02-07
US20190211028A1 (en) 2019-07-11
WO2018009899A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
JP5635544B2 (ja) ブルートンチロシンキナーゼ阻害剤
WO2020061378A1 (en) Treating sickle cell disease with a pyruvate kinase r activating compound
EP3261631B1 (en) Inhibition of olig2 activity
CN1871010B (zh) 门静脉高压的预防和/或治疗
US20210261567A1 (en) Methods for treatment of heart failure
US9149471B2 (en) Therapeutic agent for osteoporosis
AU2021291437B2 (en) Acalabrutinib maleate dosage forms
CN105418599A (zh) 新盐及医药用途
EP3852744B1 (en) Combination therapy for the treatment of uveal melanoma
CN109843868A (zh) Olig2活性的抑制
CN1655820A (zh) Pde5抑制剂与ace抑制剂的药物组合
CN103370309A (zh) 被取代的n-苯乙基三唑酮乙酰胺及其用途
EP3957310B1 (en) Composition comprising sotagliflozin and a tyrosine kinase activity inhibitor for use in the treatment of cancer
CN102008487A (zh) 法舒地尔经雾化吸入用于制备治疗肺动脉高压药物中的应用
TW200404546A (en) Novel combination
US7973066B2 (en) Pyrrolo[1,2-A]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents
JPWO1997024333A1 (ja) 糖尿病性合併症の予防・治療剤
CN104324377B (zh) 一种复方降压制剂及其应用
CN108774220B (zh) 用于治疗心肌缺血的化合物及其应用
AU2021333580A9 (en) Combination therapies with olig2 inhibitors
CN112778369A (zh) 一种三唑类衍生物及其制备方法和用途
US20080161372A1 (en) Methods for the Treatment of Hypertension
CN102503954B (zh) 咪唑衍生物、其制备方法和用途
CN1898212B (zh) 用于治疗癌症的包含苯醌的安沙霉素类似物
CN101759692B (zh) 硫代羰基化合物及其药物用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)